Analysts: Cognizant Growth Outlook Seems Healthy and 3 More Research Notes to Explore
Cognizant (NASDAQ:CTSH): After meeting with Cognizant’s management, Oppenheimer believes that the discount in the company’s stock related to immigration reform is overdone. The firm thinks the company is benefiting from strength in the banking and insurance sectors, as well as projects related to health care reform. Oppenheimer reiterates an Outperform rating on the shares.
General Mills (NYSE:GIS): Jefferies has downgraded General Mills to Underperform from Hold, citing risk to the company’s volume growth following cuts to its media spending. The firm lowered its price target for shares to $44 from $45.
Pandora (NYSE:P): Goldman Sachs has upgraded Pandora to Buy from Neutral, with a $27 price target due to accelerating mobile ads and subscription revenue growth.
Sarepta (NASDAQ:SRPT): RW Baird notes that GlaxoSmithKline (NYSE:GSK) released data showing Duchenne muscular dystrophy patients receiving its dystrophin drug may not be getting a meaningful drug effect. The firm believes this risk may benefit Sarepta, given the more favorable therapeutic index that its eteplirsen drug appears to have. Shares of Sarepta are Outperform rated with a $63 price target.
Don’t Miss: Warren Buffett’s Top 10 Favorite Stocks.